Active — Not RecruitingPhase 2

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

United States18 participantsStarted 2017-06-30

Plain-language summary

This research study is studying immunotherapy in combination with radiation therapy as a possible treatment for head \& neck cancer that has worsened or spread to another organ or part of your body. The immunotherapy involved in this study is: MK-3475 (pembrolizumab or KEYTRUDA).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓-Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

What they're measuring

Progression-Free Surival

Timeframe: 1 year

Trial details

NCT IDNCT03085719

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-11-01

Results submitted2023-10-02

View on ClinicalTrials.gov More Head and Neck Cancer trials